首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Cancer

Cancer杂志,由John Wiley and Sons Inc.出版,于1947年创刊,Semimonthly,出版语言English,ISSN:0008-543X,E-ISSN:1097-0142。

投稿咨询
Cancer
Cancer
Cancer
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
2区
影响因子
5.6
CiteScore
10.6
期刊收录
SCI、SCIE

Cancer(中文译名:《癌症》),ISSN:0008-543X,EISSN:1097-0142,是John Wiley and Sons Inc.出版的国际性学术期刊,创刊于1947年,以Semimonthly形式稳定发行,2026年总发文量约327篇。该刊采用非OA开放访问,学科归属为医学 - 肿瘤学。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达5.6,2025年期刊CiteScore为10.6,2025年期刊自引率约1.8%,在中科院期刊分区体系中位列医学大类2区TOP 期刊,在所属学科领域具备高学术影响力与国际认可度。Cancer长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期很快,2-3周,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USACanada、CHINA MAINLAND、England、GERMANY (FED REP GER)、Italy、France等为核心发文国家与地区;HARVARD UNIVERSITYUNIVERSITY OF TEXAS SYSTEM、UNIVERSITY OF CALIFORNIA SYSTEM、DANA-FARBER CANCER INSTITUTE、MEMORIAL SLOAN KETTERING CANCER CENTER、EMORY UNIVERSITY、BRIGHAM & WOMEN'S HOSPITAL等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学
2区
是 否

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学
2区
是 否

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学
2区
是 否

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 74 / 333

77.9

学科:ONCOLOGY SCIE Q1 69 / 333

79.43

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 68 / 328

79.4

学科:ONCOLOGY SCIE Q1 58 / 328

82.47


中国学者近期发文

1
Reply to Comments on chemoradiotherapy in IDH wild-type/TERT-mutant grade 2/3 glioma

Author:Zhang, Jing; Wang, Peng; Ren, Yin; Chen, Li; Feng, Jin; Liu, Fei; Deng, Kaiwen; Bao, Zhaoshi; Qiu, Xiaoguang; Liu, Yanwei

Journal: CANCER. 2026; Vol. 132, Issue 8, pp. -. DOI: 10.1002/cncr.70359

2
Diagnostic performance analysis of two-gene methylation in urothelial carcinoma based on small-volume urine sampl

Author:Wu, Zhiming; Cao, Lin; Zeng, Jiamin; Feng, Weici; Zhou, Qianghua; Deng, Xinpei; Zhang, Liang; Tan, Xingliang; Wang, Yanjun; Cao, Jiazheng; Xie, Yu; Xu, Abai; Yao, Kai

Journal: CANCER. 2026; Vol. 132, Issue 7, pp. -. DOI: 10.1002/cncr.70373

3
Final clinical data of a phase 1 dose-escalation study of WVT078, a BCMA×CD3 bispecific antibody, alone and in combination with γ-secretase inhibitor WHG626 in patients with relapsed and/or refractory multiple myelom

Author:Schjesvold, Fredrik; Spencer, Andrew; Cohen, Yael C.; Ocio, Enrique M.; Lopez‐Pardo, Jordi; Cafro, Anna Maria; Callander, Natalie S.; Kaufman, Jonathan L.; Mohan, Meera; Wermke, Martin; Doki, Noriko; Kan, Rebecca; Milanez‐Almeida, Pedro; Stein, Andrew; Trabucco, Gina; Ye, Stan; Kulec, Karolina; Sechaud, Romain; Banerjee, Souvik; Zhong, Huiqin; Lai, Clinton; Rauch, Philipp J.; Raab, Marc S

Journal: CANCER. 2026; Vol. 132, Issue 7, pp. -. DOI: 10.1002/cncr.70341

4
Poor clinical outcomes and immunoevasive contexture in gastric cancer patients bearing p16 high phenotyp

Author:Wang, Jieti; Gu, Yun; Zhang, Ziqiu; Ling, Zhen; Lin, Chao; Liu, Hao; Li, Ruochen; He, Hongyong; Shao, Fei; Xu, Jiejie

Journal: CANCER. 2026; Vol. 132, Issue 6, pp. -. DOI: 10.1002/cncr.70363

5
Durvalumab combined with concurrent chemoradiotherapy in patients with limited-stage small cell lung cancer: A prospective, single-arm, phase 2 clinical tria

Author:Song, Chunyang; Zhao, Xiaohan; Li, Shuguang; Guo, Xuehan; Zhang, Xueyuan; Wang, Xiaobin; Li, Youmei; Yan, Ke; Su, Jingwei; Xu, Jinrui; Zhu, Shuchai; Shen, Wenbin

Journal: CANCER. 2026; Vol. 132, Issue 6, pp. -. DOI: 10.1002/cncr.70351

6
Long-term outcomes of newly diagnosed POEMS syndrome patients treated with bortezomib-based therapie

Author:He, Haiyan; Fu, Qingcheng; Yu, Xuerou; Chen, Xi; Lu, Jing; Jin, Lina; Fan, Xiaoqiang; Du, Juan

Journal: CANCER. 2026; Vol. 132, Issue 4, pp. -. DOI: 10.1002/cncr.70293

7
T-cell receptor-like chimeric antigen receptor T cells targeting mesothelin: A first-in-human dose-escalation trial for platinum-resistant advanced ovarian cance

Author:Shan, Yiyang; Ding, Bo; Ji, Feng; Lin, Hao; Shi, Weiwei; Wang, Enxiu; Wang, Chen; Shen, Yang

Journal: CANCER. 2026; Vol. 132, Issue 3, pp. -. DOI: 10.1002/cncr.70279

8
The evolution and prognostic impact of HER2-low, HER2-ultralow, and HER2-null status in HER2-negative early breast cancer: A pre- to post-neoadjuvant chemotherapy stud

Author:Qiu, Yibin; Wu, Long; Cai, Weifeng; Chen, Minyan; Jiang, Meichen; Wang, Yali; Liu, Shunyi; He, Peng; Lin, Yuxiang; Chen, Lili; Yang, Yinghong; Wang, Chuan; Zhang, Jie; Fu, Fangmeng

Journal: CANCER. 2026; Vol. 132, Issue 3, pp. -. DOI: 10.1002/cncr.70269

9
The safety of trastuzumab deruxtecan (T-DXd) in breast cancer brain metastases with a focus on interstitial lung disease/pneumonitis: A systematic review and meta-analysi

Author:Ma, Yiwen; Li, Xiaorui; Jiang, Yujun; Xiao, Liping; Sun, Tao

Journal: CANCER. 2026; Vol. 132, Issue 3, pp. -. DOI: 10.1002/cncr.70268

10
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma: A cost-effectiveness analysi

Author:Luo, Jiefeng; Li, Zhengxiong; Ge, Jun; Cai, Sizhen; Mo, Xinyi; Liu, Wensheng; Gui, Chengxia; Du, Qiong; Liu, Jiyong

Journal: CANCER. 2026; Vol. 132, Issue 3, pp. -. DOI: 10.1002/cncr.70259


在线咨询

Cancer

国际简称:CANCER-AM CANCER SOC参考译名:癌症

年发文量:327 CiteScore:10.6 是否预警:否 Gold OA文章占比:40.30% 研究类文章占比:88.69%

杂志社联系方式:JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, USA, NJ, 07030

Cancer